Chemotherapy Regimens and Survival in Pancreatic Cancer-A Ten-Year Single Centre Overview.

ABSTRACT:

Background

During the last decade chemotherapy recommendations have changed for patients with pancreatic adenocarcinoma (PDAC) as novel regimens demonstrate better survival in selected cohorts. Herein we aim to, in a regional cohort, analyse therapy changes and possible survival benefits over a 10-year period.

Methods

Patients in the southern region of Sweden diagnosed with pancreatic cancer between 2010 and 2011 (Early group) and 2018 and 2019 (Late group), were enrolled from the Swedish Pancreatic Cancer Registry. Baseline characteristics and chemotherapy regimens were obtained from medical records. Resected and palliative patients were analysed separately.

Results

A total of 323 patients with PDAC were included: 81 resected and 242 palliative, 147 within the Early

SUBMITTER: Tranvik H 

PROVIDER: S-EPMC12672207 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature